Avic Commitment to Brazil

Special Tips

Wednesday, February 27, 2013

Bio-Coccivet R for commercial laying

.

Bio-Coccivet R conquers new markets

Over the past years the vaccine Bio-Coccivet-R has been occupying the lead position without precedents in the heavy and light breeder segment. Since 2010, for example, it has been used by 95% of this market. The distinguished position was achieved due to the perception of the poultry segment of the technical advantages of the product in the face of its international competitors, such as in its self-sufficiency and capacity of overcoming the challenges faced in the field.

The success of Bio-Coccivet R raised the interest of commercial layer farmers. Those that rear their "part-time" birds on a bed and the remaining time in cages, as well as those that maintain "full-time" rearing in battery system with different floors of cages, explains Dr. Juan Solis, technical advisor of Biovet Laboratory and internationally known researcher in the area of avian coccidiosis, responsible for the technical development of Bio-Coccivet R.

Dr. Solis said "unfortunately researches have shown that coccidiosis also causes great loss in the commercial layer sector". It is not by chance. Avian coccidiosis is a parasitic disease that affects the intestinal health of birds, mainly causing the drop in production and opening the way to other diseases.

Owner of the experience acquired during the intense and meticulous studies conducted for the development of Bio-Coccivet R, Biovet Laboratory was recently sought out by layer farmers. The reason was to certify that their birds were really being affected by the avian coccidiosis.

Vaccination method for commercial layer
The work began with the collection of material to conduct tests. Samples of coccidian strains isolated from the intestine and cecum of commercial birds of different ages were studied. The eimeria species found were isolated, purified and identified using PCR (the same state of the art technology used in the development and production of the vaccine Bio-Coccviet R).

There were in-depth researches on bacteria from cages specially mounted in the Technical Center for Eimeria Reproduction of the Biovet Laboratory located in Ibiúna (SP). At the end of these works, the presence of field pathogenic strains was confirmed, which compromise the performance of the commercial layers during their various periods of life.

Based on these studies, Dr. Juan Solis and the technical team of Biovet Laboratory developed a vaccination method with Bio-Coccivet R specific for the commercial laying sector. This, associated to handling prescriptions also specific for chickens kept in cages, allows the recycling of vaccinal Eimeria in order to obtain the solid and rapid development of immunity against the coccidiosis in birds.

Future vision
Today, Bio-Coccivet R provides for the heavy and light breeder market besides the commercial layers in Brazil as well as in Bolivia and in Peru. The success is due to a number of factors. For example, constant researches are conducted by Dr. Juan Solis at the Technical Center for Eimeria Reproduction located in Ibiúna. It is worth emphasizing that these precautions started from the beginning of the works of this unit of Biovet Laboratory.

It was of extreme importance during the development stage of Bio-Coccivet R to have selected the more protective antigenic strains for use in the product. After all, the immune response obtained through vaccines is not only species-specific, existing the possibility of inter-species variation (including with the existence of variant strains).

These works proceed considering the release of new products in future, according to the needs and challenges of the sector.

Go Back